INTERLEUKIN-6 RECEPTOR INHIBITORS IN THE MANAGEMENT OF PATIENTS WITH SEVERE SARS-COV-2 PNEUMONIA
- Funded by Lundbeck Foundation
- Total publications:0 publications
Grant number: unknown
Grant search
Key facts
Disease
COVID-19start year
2020Known Financial Commitments (USD)
$587,850Funder
Lundbeck FoundationPrincipal Investigator
N/A
Research Location
DenmarkLead Research Institution
Bispebjerg HospitalResearch Priority Alignment
N/A
Research Category
Clinical characterisation and management
Research Subcategory
Clinical trials for disease management
Special Interest Tags
N/A
Study Type
Clinical
Clinical Trial Details
Randomized Controlled Trial
Broad Policy Alignment
Pending
Age Group
Unspecified
Vulnerable Population
Unspecified
Occupations of Interest
Unspecified
Abstract
Data from China indicate that a known anti-rheumatism drug may have an inhibitory effect on the inflammation that damages patients' lungs when they contract COVID-19. In a controlled, randomised trial, the researchers at Bispebjerg Hospital will investigate whether the assumptions about the beneficial effect of this drug hold water.